<DOC>
	<DOCNO>NCT02686814</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness 17mm MDT-2215 aortic valve bioprosthesis .</brief_summary>
	<brief_title>PERIGON Japan Trial</brief_title>
	<detailed_description>This prospective , interventional , non-randomized , multi-center trial , site follow common protocol Japan . A maximum 20 subject implant maximum 10 site Japan . The trial include male female patient legal age provide inform consent Japan , require replacement diseased , damage , malfunction native prosthetic aortic valve . Patients follow assessed implant 5 year .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Patient severe aortic stenosis regurgitation , clinical indication replacement native prosthetic aortic valve bioprosthesis , without concomitant procedure , limit following : Left atrial appendage ( LAA ) ligation Coronary artery bypass graft ( CABG ) Patent foramen ovale ( PFO ) closure Ascending aortic aneurysm dissection repair require circulatory arrest Resection subaortic membrane require myectomy 2 . Patient geographically stable willing return implant site followup visit 3 . Patient legal age provide inform consent 4 . Patient adequately inform risk requirement trial willing able provide inform consent participation clinical trial 5 . In opinion investigator , preoperative imaging indicate patient may suitable 17mm size valve 1 . Patient preexist prosthetic valve annuloplasty device another position require replacement repair mitral , pulmonary tricuspid valve 2 . Patient previous implant explant MDT2215 aortic valve bioprosthesis 3 . Patient present active endocarditis , active myocarditis systemic infection 4 . Patient anatomical abnormality would increase surgical risk morbidity mortality , include : Ascending aortic aneurysm dissection repair require circulatory arrest Acute type A aortic dissection Ventricular aneurysm Porcelain aorta Hostile mediastinum Hypertrophic obstructive cardiomyopathy ( HOCM ) Documented pulmonary hypertension ( systolic &gt; 60mmHg ) 5 . Patient noncardiac major progressive disease , life expectancy le 2 year . These condition include , limited : ChildPugh Class C liver disease Terminal cancer Endstage lung disease 6 . Patient renal failure , define dialysis therapy glomerular filtration rate ( GFR ) &lt; 30 mL/min/1.73 m2 7 . Patient hyperparathyroidism 8 . Patient participate another investigational device drug trial observational competitive study 9 . Patient pregnant , lactate plan become pregnant 10 . Patient document history substance ( drug alcohol ) abuse 11 . Patient great mild mitral valve regurgitation great mild tricuspid valve regurgitation assess echocardiography 12 . Patient systolic ejection fraction ( EF ) &lt; 20 % assess echocardiography 13 . Patient grade IV diastolic dysfunction 14 . Patient document bleeding diatheses 15 . Patient acute preoperative neurological deficit myocardial infarction return baseline stabilize â‰¥30 day prior enrollment 16 . Patient require emergency surgery 17 . Patient NYHA Class I 18 . Operative 1 . ) Prior attempt implant MDT2215 valve , identify patient require concomitant procedure allow per enrollment exclusion criterion 2 . ) Patient anatomy suitable implant size 17mm MDT2215 aortic valve bioprosthesis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Valvular heart disease</keyword>
	<keyword>Severe aortic stenosis</keyword>
	<keyword>Aortic valve replacement</keyword>
</DOC>